A novel blood preservation technique, CryoSCAPE, developed by researchers at the Allen Institute for Immunology, promises to overcome limitations in blood sample analysis for research and clinical trials. This method, detailed in the Journal of Translational Medicine, addresses the critical issue of molecular changes that occur in blood samples within hours of collection.

Blood analysis is a crucial tool for understanding human health, but its molecular composition can alter significantly within 6-8 hours of collection. This time sensitivity has restricted blood-based research and clinical trials to areas near major research centers, limiting our understanding of diverse populations, especially in rural or underserved communities.

CryoSCAPE uses a simple chemical mixture to put blood into a "suspended animation," preserving delicate molecules in their natural state and protecting them during freezing.

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

“Virtually all clinical trials run by biopharmaceutical companies will collect blood at one site, but then they have to ship the blood overnight to a centralized processing site,” explained Peter Skene, senior author of the paper. "We wanted to solve this problem by developing a methodology that allows immediate blood stabilization at the bedside."

This innovation is particularly valuable for single-cell technologies, which analyze individual cells' molecular composition. The Allen Institute team found that RNA sequencing data changes completely just six hours after blood collection, but CryoSCAPE could maintain the sample's integrity.

The method also scales up single-cell experiments, allowing processing of hundreds of blood samples simultaneously. This scalability could broaden the reach of immunology studies and increase participation from underserved communities in research and clinical trials.

The Allen Institute team aims to make this technology more accessible, potentially revolutionizing blood-based research and clinical trials by enabling sample collection from a wider range of locations and populations.